It's actually one of my favorite stocks! ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

Loyal reader since June 2022

View in browser SPONSORED HUGE Overnight Trade Opportunity During Election Week?! I closed biggest Overnight Trades during just ONE week: 214%... 190%... and as much as 293% gains... But the week of the election could bring the BIGGEST opportunities yet! For the first time ever... you can join our FREE Open House during Election Week (November 4 - 8). You can get ALL of our trade recommendations (including the Overnight Trades)... Plus... we'll have a Post Election Livestream Trading Event! Go Here to Join Us for Free (No Cost... No Obligation... No BS!) SAFETY NET This Drug Giant's Dividend Isn't as Scary as It Looks Marc Lichtenfeld, Chief Income Strategist, The Oxford Club Since Halloween is tomorrow, in this week's Safety Net, we're going to take a look at a dividend that many investors are afraid of. For as long as I can remember, Wall Street has been scared silly about AbbVie (NYSE: ABBV). The rub on AbbVie is that Humira, the company's top revenue generator and the biggest-selling drug in the world, is now off-patent. For many years, Wall Street analysts advised investors to stay away, warning that when Humira's patent expired, generics would flood the market and cause AbbVie's revenue, earnings, and stock price to crater as a result. But in reality, the company is as terrifying as a polite 4-year-old trick-or-treater in a princess costume. The chart below shows how wrong Wall Street analysts have been about AbbVie. View larger image   Even now, more than a third of analysts that cover the stock don't rate it a "Buy." But I never let the "Wrong Way Corrigan" analysts influence me. AbbVie has been in the Compound Income Portfolio in my monthly newsletter, The Oxford Income Letter, since 2016. With dividends reinvested, we're sitting on a gain of 376% and enjoying an annual yield of 10.8% on our original investment. AbbVie is a Perpetual Dividend Raiser, having boosted its dividend every year since it was spun off from Abbott Laboratories (NYSE: ABT) in 2013. It currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price. Can AbbVie continue to be a Perpetual Dividend Raiser? SPONSORED Discover the Hidden Gold Play Wall Street Is Ignoring While everyone is chasing gold at $2,500 per ounce, there's a little-known investment that gives you exposure to over 1 oz of gold — for less than $20. And the best part? It has outperformed gold by 10-to-1 over the past 25 years. Click here now to seize this opportunity before the next surge. In the second quarter, Humira sales dropped 29% year over year. As a result, the company's free cash flow is forecast to decline from $22.1 billion last year to $17.6 billion in 2024. However, AbbVie is only expected to pay $11.1 billion in dividends for a payout ratio of 63%, which is well within my comfort range. I like to see companies' payout ratios stay below 75% of their free cash flow. That tells me that even if free cash flow declines, the company should be able to afford its dividend going forward. Plus, as I said above, AbbVie has boosted its dividend every year for 11 years, showing investors its commitment to dividend growth. View larger image   Considering all of that - the decline in Humira sales, the payout ratio, the dividend track record, etc. - what grade would you give AbbVie's dividend? Click the button below to let me know your thoughts in the comments. Then scroll up to reveal my dividend safety rating. Share Your Grade Here! BUILD AND PROTECT YOUR WEALTH Discover the Top Passive Income Opportunity for 2024... Election Scenarios and Their Impact on Markets Former CBOE Trading Legend Showed Members 246% Total Gains While the S&P Was Down 20% During the COVID Crash. Now He's Hosting a Free Class Revealing the Answer to Big Wins. Click for More! Does the American Dream Really Cost $4.4 Million? MORE FROM WEALTHY RETIREMENT Is a Democratic or Republican President Better for Stocks? This Cannabis Giant's Bargain Price May Be a Trap The Safety Net System: How I Evaluate Companies' Dividends How Politics Can Ruin Your Portfolio Facebook LinkedIn Email Share Push Alert SPONSORED Top Stock Forecaster: "Buy These Stocks Before Trump Takes Office" Weekly Fox Business guest who accurately predicted President's Trump's first Stockwave says the Dow could skyrocket to 75,000 with Trump back in office. The last time he was in office, stocks rose as much as 3,480%... See what stocks could surge this time: Click here to see the details. You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.808.9795 | International: +1.443.353.4621 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.